A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Gilteritinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms MORPHO
- Sponsors Astellas Pharma
- 12 Sep 2017 Planned End Date changed from 1 Jul 2024 to 1 Aug 2024.
- 12 Sep 2017 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2024.
- 21 Aug 2017 According to an Astellas Pharma media release, first patient has been dosed.